Last reviewed · How we verify

Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose — Competitive Intelligence Brief

Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose (variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine. Area: Immunology.

marketed mRNA vaccine SARS-CoV-2 Immunology Live · refreshed every 30 min

Target snapshot

Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose (variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose TARGET variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose Pfizer marketed mRNA vaccine SARS-CoV-2
PF-07321332 Dose 5 pf-07321332-dose-5 Pfizer marketed Protease inhibitor Main protease (MPro) of SARS-CoV-2 Pending regulatory approval
Paxlovid (Copackaged) Nirmatrelvir Pfizer marketed Antiviral protease inhibitor SARS-CoV-2 main protease (Mpro, 3CLpro, nsp5 protease) 2023-01-01
Comirnaty BNT162b2 (tozinameran) Pfizer Inc. marketed vaccine SARS-CoV-2 virus 2021-08-23
Veklury remdesivir Gilead Sciences marketed Nucleotide analog RNA polymerase inhibitor SARS-CoV-2 RNA polymerase 2020-01-01
CCP CCP Metro Infectious Disease Consultants marketed Convalescent plasma SARS-CoV-2 spike protein and other viral antigens
mRNA-1273 Variant-containing Formulation mRNA-1273 Variant-containing Formulation ModernaTX, Inc. marketed mRNA vaccine SARS-CoV-2 spike protein (variant-specific)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (mRNA vaccine class)

  1. Pfizer · 12 drugs in this class
  2. ModernaTX, Inc. · 11 drugs in this class
  3. BioNTech SE · 5 drugs in this class
  4. Jules Bordet Institute · 5 drugs in this class
  5. Tan Tock Seng Hospital · 2 drugs in this class
  6. Clover Biopharmaceuticals AUS Pty · 1 drug in this class
  7. CanSino Biologics Inc. · 1 drug in this class
  8. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  9. CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
  10. Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose — Competitive Intelligence Brief. https://druglandscape.com/ci/variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: